ClinicalCodes.org
An online clinical codes repository to improve validity and reproducibility of medical database research
Research article:
HbA1C variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: a nested case-control study
Reference:
Victor W. Zhong; Juhaeri Juhaeri; Stephen R. Cole; Christina M. Shay; Penny Gordon-Larsen; Evangelos Kontopantelis; Elizabeth J Mayer-Davis(2017) HbA1C variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: a nested case-control study. Journal of Diabetes and its Complications, doi: http://dx.doi.org/10.1016/j.jdiacomp.2017.10.008
- Link to article
- Abstract
- Aims: To determine association between HbA1C variability and hypoglycemia requiring hospitalization (HH) in adults with type 1 diabetes (T1D) and type 2 diabetes (T2D). Methods: Using nested case-control design in electronic health record data in England, one case with first or recurrent HH was matched to one control who had not experienced HH in incident T1D and T2D adults. HbA1C variability was determined by standard deviation of ≥3 HbA1C results. Conditional logistic models were applied to determine association of HbA1C variability with first and recurrent HH. Results: In T1D, every 1.0% increase in HbA1C variability was associated with 90% higher first HH risk (95% CI, 1.25-2.89) and 392% higher recurrent HH risk (95% CI, 1.17- 20.61). In T2D, a 1.0% increase in HbA1C variability was associated with 556% higher first HH risk (95% CI, 3.88-11.08) and 573% higher recurrent HH risk (95% CI, 1.59-28.51). In T2D for first HH, the association was the strongest in non-insulin non-sulfonylurea users (P<0.0001); for recurrent HH, the association was stronger in insulin users than sulfonylurea users (P=0.07). The HbA1C variability-HH association was stronger in more recent years in T2D (P≤0.004). Conclusions: HbA1C variability is a strong predictor for HH in T1D and T2D.
- Author for correspondence
- Elizabeth J Mayer-Davis
- Email for correspondence
- mayerdav@email.unc.edu
Code list: res50: acarbose
4 codes in list
| Code | Coding system | Description | Entity type | List name | drugsubstance | bnfcode | bnfchapter |
|---|---|---|---|---|---|---|---|
| 479 | CPRD_product_code | Acarbose 50mg tablets | drug | res50: acarbose | Acarbose | 6010203 | Other Antidiabetic Drugs |
| 5174 | CPRD_product_code | Acarbose 100mg tablets | drug | res50: acarbose | Acarbose | 6010203 | Other Antidiabetic Drugs |
| 5621 | CPRD_product_code | Glucobay 50mg tablets (Bayer Plc) | drug | res50: acarbose | Acarbose | 6010203 | Other Antidiabetic Drugs |
| 9105 | CPRD_product_code | Glucobay 100mg tablets (Bayer Plc) | drug | res50: acarbose | Acarbose | 6010203 | Other Antidiabetic Drugs |
Please log in to leave a comment.
Code list links:
ClinicalCodes is a project at the University of Manchester Institute of Population Health
The ClinicalCodes project is funded by the National Institute for Health Research (NIHR) School for Primary Care Research (SPCR)